Tuberculosis is still one of the deadliest infectious diseases, causing over one million deaths each year worldwide. On the other hand, about one-fourth of the world's population carries Mycobacterium tuberculosis (M. tuberculosis) without showing any symptoms, and most of these carriers do not develop the disease.

In a critical global public health development, a candidate vaccine for tuberculosis (TB) has been created using a gene-editing approach.

The World Health Organization (WHO) is seeking experts to serve as members on WHO Technical Advisory Group on clinical and policy considerations for new TB vaccines.

The International Union Against Tuberculosis and Lung Disease released the June 2024 issue of IJTLD OPEN – a fully-compliant, open access journal to enhance the coverage of TB and lung disease.

Officials from several Ministries of Health have written to Danaher requesting that the price of the tests for XDR-TB, HIV and hepatitis — currently priced at $14.90 per test cartridge — also be lowered to no more than $7.97. 

The formulation was developed through a single emulsion solvent evaporation technique and offers new delivery approach which could improve patient compliance, the paper stated.

In patients with latent tuberculosis, influenza-like reactions following treatment with isoniazid plus rifapentine or isoniazid alone were not associated with the presence of antibodies against isoniazid, rifapentine, and rifapentine metabolite.

The SMART4TB Consortium will host a webinar on 20 June 2024 about the consensus process and statement for earlier inclusion of pregnant women and persons in TB research. Simultaneous translation will be available in French, Spanish, Portuguese and Russian.

RESIST-TB released its June 2024 newsletter with the latest updates and research publications on drug-resistant TB.